$SNYNF News Article - Press Release: Sarclisa (is
Post# of 9
(Total Views: 76)
Posted On: 12/07/2023 8:25:45 AM
$SNYNF News Article - Press Release: Sarclisa (isatuximab) Phase 3 trial met primary endpoint of progression free survival in patients with newly diagnosed multiple myeloma not eligible for transplant https://marketwirenews.com/news-releases/pres...90596.html
(0)
(0)Sanofi-Aventis Sa (SNYNF) Stock Research Links
My Twitter: WhyteStocks
Scroll down for more posts ▼